Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Non-Current Assets (2018 - 2025)

X4 Pharmaceuticals' Non-Current Assets history spans 8 years, with the latest figure at $28.9 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 15.72% year-over-year to $28.9 million; the TTM value through Dec 2025 reached $126.2 million, down 2.57%, while the annual FY2025 figure was $28.9 million, 15.72% down from the prior year.
  • Non-Current Assets reached $28.9 million in Q4 2025 per XFOR's latest filing, down from $30.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $41.1 million in Q1 2021 to a low of $24.8 million in Q1 2024.
  • Average Non-Current Assets over 5 years is $31.0 million, with a median of $29.1 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: crashed 30.46% in 2022, then skyrocketed 38.44% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $29.3 million in 2021, then decreased by 8.15% to $26.9 million in 2022, then dropped by 6.42% to $25.2 million in 2023, then skyrocketed by 36.1% to $34.3 million in 2024, then decreased by 15.72% to $28.9 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Non-Current Assets are $28.9 million (Q4 2025), $30.8 million (Q3 2025), and $32.2 million (Q2 2025).